Gate Bioscience expands collaboration with Eli Lilly, potential value above $870 million

Gate Bioscience has expanded its collaboration with Eli Lilly, with potential value exceeding $870 million. The alliance adds a drug target and contemplates another; Gate will lead discovery while Lilly takes on development and exclusive global rights.

Detected & updated continuously · Source: Nebula